Pulmonary embolism management has evolved considerably beyond anticoagulation alone, driven largely by advances in catheter-based device technology. Today's device landscape spans several distinct approaches, each suited to a different clinical scenario. This overview walks through the major categories in use and how they fit together within a modern PE treatment pathway.
Catheter-Directed Thrombolysis: Targeted Drug Delivery
Catheter-directed thrombolysis (CDT) delivers a clot-dissolving medication directly into the pulmonary artery through a catheter positioned at or near the thrombus, rather than relying on the medication circulating systemically. This localized delivery is intended to concentrate the drug's effect at the clot while using a lower overall dose than systemic thrombolysis might require. Some systems combine this drug delivery with ultrasonic energy, a pharmacomechanical approach intended to help disrupt the clot's fibrin structure and potentially improve drug penetration.
Large-Bore Aspiration Thrombectomy: Mechanical Clot Removal
Large-bore aspiration systems use a wide catheter lumen and vacuum-based suction to physically remove clot material from the pulmonary arteries without relying on thrombolytic medication. This approach can be particularly relevant for patients with a large central clot burden or for those in whom thrombolytic drugs carry elevated bleeding risk. Device design in this category often incorporates capture structures intended to contain fragmented clot material during removal, reducing the risk of distal embolization during the procedure itself.
Rotational and Pharmacomechanical Thrombectomy
Some thrombectomy platforms combine rotational fragmentation with active aspiration, intended to break down more organized or chronic clot material before removing it from the vasculature. This pharmacomechanical approach can be adapted for varying clot consistencies, and adjustable rotational control allows the operator to modulate the device's action based on how the thrombus responds during the case.
Retrievable IVC Filters: A Complementary, Not Competing, Technology
Distinct from the clot-removal technologies above, retrievable IVC filters serve a preventive rather than therapeutic role, intercepting clot fragments traveling from the legs or pelvis toward the lungs. Filters are typically considered when anticoagulation is contraindicated or when periprocedural embolic protection is needed during a separate DVT intervention. Because they address a different point in the disease pathway, filters are often used alongside — rather than instead of — the clot-removal technologies described above.
How These Technologies Fit Into a Treatment Pathway
None of these device categories is universally superior; the appropriate choice depends on clot burden, location, the patient's hemodynamic status, and contraindications to anticoagulation or thrombolytic therapy. Many hospitals rely on a pulmonary embolism response team to weigh these factors and select an approach tailored to the individual patient, often integrating input from interventional radiology, cardiology, and critical care.
Where INVAMED's Portfolio Sits Within This Landscape
INVAMED manufactures devices spanning several of these categories, including the AngioHAND Clot Removal Catheter for aspiration-based thrombus extraction, the Viper ULTRA Thrombolysis Catheter for pharmacomechanical, ultrasound-assisted clot dissolution (per manufacturer-reported product description), and the MultiBEAM Inferior Vena Cava (IVC) Filter for retrievable filtration. Full indications, contraindications, and technique guidance for each device are found in their respective Instructions for Use (IFU); the complete category is detailed on INVAMED's pulmonary embolism management page.
How has the PE device landscape changed in recent years?
The field has moved toward more device-based options that reduce clot burden mechanically or pharmacomechanically, offering alternatives for patients who may not be ideal candidates for systemic thrombolysis or who need more rapid intervention than anticoagulation alone provides. This evolution has coincided with growth in multidisciplinary care models designed to match patients to the appropriate technology.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.